The synthesis of some derivatives based on the 4-Benzyl-1H-Pyrazole-3,5- Diamine core

Article abstract of DOI:10.3987/COM-10-12101

The three-step synthesis of 4-benzyl-1H-pyrazole-3,5-diamines 2 from commercially available aldehydes 3 is given. The Knoevenagel condensation was utilized to assemble the initial carbon framework, resulting in the benzylidenemalononitriles 4 which were d

Full text of DOI:10.3987/COM-10-12101

HETEROCYCLES, Vol. 83, No. 2, 2011
371
HETEROCYCLES, Vol. 83, No. 2, 2011, pp. 371 - 383. © The Japan Institute of Heterocyclic Chemistry
Received, 9th November, 2010, Accepted, 9th December, 2010, Published online, 27th December, 2010
DOI: 10.3987/COM-10-12101
THE SYNTHESIS OF SOME DERIVATIVES BASED ON THE
4-BENZYL-1H-PYRAZOLE-3,5-DIAMINE CORE
Lukáš Jedinák,a Vladimír Kryštof,b and Petr Cankařa*
aDepartment of Organic Chemistry, Palacký University, 17. listopadu 1192/12,
771 46 Olomouc, Czech Republic. E-mail: cankar@orgchem.upol.cz
Tel: +420585634437, Fax: +420585634465
bLaboratory of Growth Regulators, Institute of Experimental Botany, AS CR and
Palacký University, Slechtitelu 11, 783 71 Olomouc, Czech Republic
Abstract – The three-step synthesis of 4-benzyl-1H-pyrazole-3,5-diamines 2 from
commercially available aldehydes 3 is given. The Knoevenagel condensation was
utilized to assemble the initial carbon framework, resulting in the
benzylidenemalononitriles 4 which were directly transformed by the reduction of
the electron deficient C=C bond to benzylmalononitriles 5. Subsequent
cycloaddition of hydrazine with 5 afforded the desired pyrazoles 2. Due to the
high similarity with 4-arylazo-1H-pyrazole-3,5-diamines, the biological activities
of the 4-benzyl-1H-pyrazole-3,5-diamines 2 were evaluated while focusing on the
inhibition of cyclin-dependent kinases (CDKs), but no significant results were
obtained.
In the last decade, protein kinases became an important class of drug targets for the pharmaceutical
industry for the treatment of proliferative disorders such as cancer and inflammation.1-4 The successful
development of these molecular inhibitors resulted in the launch of several drug candidates that are
currently on the market. Some examples of this class of drug that are commercially available include
imatinib, dasatinib and nilotinib.5 This selection, of course, only partially illustrates the vast amount of
research completed in the area of protein kinase inhibitors.
A few years ago, we reported that the 4-arylazopyrazole-3,5-diamine derivatives 1 (Scheme 1) showed
significant inhibitory activity against cyclin-dependent kinases (CDKs).6 The most potent derivative,
CAN508, displayed selectivity toward CDK9.6 Inhibition of CDK9, which is the catalytic subunit of

372
HETEROCYCLES, Vol. 83, No. 2, 2011
positive transcription elongation factor b (P-TEFb),7 can potentially play an important role in cardiac
muscle-cell hyperthrophy,8 HIV-1 Tat protein transactivation9,10 or even cancers11,12 and therefore is of
potential pharmaceutical interest.
If the structures of low molecular weight protein kinase inhibitors are examined in more detail, some
similar structural features can be traced.13 The inhibitor CAN508 contains a rigid pyrazole ring and a
benzene ring that are connected by an azo group moiety. Many compounds containing an azo group are
considered to be non-toxic; some, such as tartrazine (E102), still are used as food additives.14 However, in
recent years, several reports suggest their possible genotoxicity and a possible role in cancer induction.15
Therefore, we attempted to replace this pharmacologically unfavorable functionality by substituting a
methylene group for the azo group, as in pyrazole 2. Additionally, we were interested in how the
methylene linker would change the inhibitory activity against CDKs. Therefore, we selected
commercially available starting materials to provide benzene-substituted pyrazole products with
functional groups more likely to interact with the active site of the protein kinase. The pyrazoles 2b,16
2e17 and 2f18 have previously been reported but usually as intermediates in a multi-step synthesis, and
the preparation of only a limited number of benzene-substituted derivatives has been described.
H2N
H2N
NH2
H2
C
N
N
NH
azo group
modification
R
NH
R
N
N
NH
N
N
N
NH2
NH2
H2N
by the CH2
group
HO
CAN508
1
2
Scheme 1
RESULTS AND DISCUSSION
The synthesis of the pyrazole derivative 2 was completed in three steps (Scheme 2). The carbon
framework was assembled in the first step using a Knoevenagel condensation of an aldehyde and
malononitrile. The activated C=C bond of the benzylidenemalononitrile derivative 4 was reduced to give
benzylmalononitrile 5. The alternative preparation of derivatives of 5 via the alkylation of malononitrile
with a benzyl halide is not ideal for the following two reasons: the reaction usually results in the
formation of bis-benzylated malononitriles, and more aldehydes are generally commercially available
than benzyl halides.19,20 Finally, the synthesis was completed by the cycloaddition of hydrazine and 5 to
afford the desired pyrazoles 2.
Our primary intention was to develop a practical method to utilize diverse substituted benzaldehyde
derivatives 3 in a Knoevenagel condensation with malononitrile. To find suitable robust reaction

HETEROCYCLES, Vol. 83, No. 2, 2011
373
conditions, benzaldehydes 3a, 3b and 3c were chosen for a model study. THF was used as the solvent
because a wide range benzaldehyde derivatives are typically very soluble in it. Another reason to use this
aprotic solvent was the possibility of performing the Knoevenagel condensation and the subsequent
reductive step in a one-pot synthesis, eliminating the need to isolate the intermediate 4. Although the
Knoevenagel condensation was studied using various catalysts21-23 and even performed in water alone
without a catalyst,24 we found the classical catalyst piperidine to be the most suitable in this case.
At first, we investigated the necessary concentration of piperidine at ambient temperature. The amount of
piperidine was critical during the condensation of the most reactive aldehyde 3b so that the product 4b
could be isolated in high purity. One mole percent of piperidine was found to be sufficient for complete
condensation without any decrease in purity or yield. The reaction time was extended to 24 hours for the
less reactive aldehydes 3a and 3c. In general, the optimized reaction conditions (THF, 1% piperidine, rt,
24 h) were found to be applicable for all selected aldehydes 3a-o, and yields of the isolated
benzylidenemalononitriles 4a-d were higher than 80%. Except for the benzylidenemalononitriles 4a and
4b, which were isolated for model study purposes, only the benzylidenemalononitriles 4c and 4d were
isolated and characterized because no data for these analogs was previously published.
Benzylidenemalononitriles 4e-o were directly reduced to benzylmalononitriles 5 without an isolation of
the intermediates 4.
R
R
R
CN
CN
CN
malononitrile
1 % piperidine
O
NaBH3CN, AcOH
THF, rt, 3 h
CN
THF, rt, 24 h
3a-o
5a-o
4a-o
N2H4, MeOH
reflux, 8 h
a: R = 4-OH
f: R = 4-OMe
g: R = 3-OH
h: R = 3-F
: R = 4-F
: R = 2,3,4,5,6-F
k: R = 2-Cl, 6-F
b
l
: R = 4-NO2
c: R = 2,6-Me
: R = 2-F
m: R = 2-NO2
NH2
NH
R
i
j
d
e
n
o
: R = 2,6-Cl
: R = 3-NO2
: R = 3-OMe
: R = 2-OMe
N
H2N
2a-o
Scheme 2
The second step, the reduction of a C=C bond, was optimized using purified benzylidenemalononitriles
4a and 4b. Although it is possible to find references describing the C=C bond reduction of some
benzylidenemalononitriles,25-28 we decided to use sodium cyanoborohydride as a new alternative reducing

374
HETEROCYCLES, Vol. 83, No. 2, 2011
agent for the electron deficient C=C bond in intermediates 4. Some authors, when describing the
reduction of heterocyclic systems with sodium cyanoborohydride, indicate that it might also be efficient
in our system.29-31 The first attempt to reduce 4a or 4b with sodium cyanoborohydride in THF at ambient
temperature afforded only a mixture of compounds, but no desired benzylmalononitriles 5a or 5b were
detected by HPLC/MS. When the same reaction was carried out in the presence of acetic acid,
benzylmalononitriles 5a and 5b were the major products, and after work up, they were easily isolated by
filtration. Next, we focused our effort on the preparation of benzylmalononitriles 5a and 5b directly from
the corresponding aldehydes 3a and 3b without the need to isolate the intermediate
benzylidenemalononitriles 4a and 4b. A simple one-pot procedure was developed as follows. After the
first condensation step was completed, a THF solution containing sodium cyanoborohydride and acetic
acid was added, and the resulting reaction mixture was continuously stirred for an additional three hours.
The resulting benzylmalononitriles 5a-o were then isolated by filtration or extraction and purified by
recrystallization or chromatography. This one-pot synthetic strategy was applied for the preparation of all
benzylmalononitriles 5a-o with yields ranging between 37 and 70% over the two steps.
Several attempts to synthesize pyrazoles 2 from benzylmalononitriles 5a and 5b in a one-pot procedure
were carried out. Because the cycloaddition reaction with hydrazine hydrate in boiling THF failed, it was
obvious that the preceding isolation of benzylmalononitrile 5 is necessary. The cyclization proceeds in
EtOH but was troublesome due to the formation of greasy products that were difficult to isolate when
using the reported procedure for benzene-unsubstituted derivatives.32 Despite our difficulties using EtOH
in the final step, MeOH was found to be a suitable solvent. Utilization of MeOH enabled to simplify the
isolation of cycloaddition reaction products. The pyrazoles 2a-o, prepared from corresponding
benzylmalononitriles 5a-o with hydrazine hydrate in boiling MeOH, were obtained in yields between 29
and 88%. Isolation of the pyrazoles 2a-l was simple. After evaporation of MeOH, the residue was
triturated with DCM or recrystallized from a mixture of MeOH and ethyl acetate. The attempts to isolate
pure pyrazoles 2m-o as a free base or a hydrochloride salt failed, although they were identified as part of
the reaction mixture by HPLC-MS.
In the 13C NMR spectra of the isolated compounds, we observed an unusual overlap of carbon signals for
pyrazole 2d. The HSQC NMR spectrum revealed that carbon signals representing the meta and para
13
position were overlapped, so the C NMR spectrum showed only 6 singlets instead of the expected 7
singlets. In addition to this result, another complication can occur when measuring the 13C NMR
spectrum of pyrazole 2. The pyrazole carbon signal around 149 ppm, common to all the pyrazoles we
isolated, was difficult to observe in some derivatives. The signal is broadened probably due to
tautomerism of the pyrazole ring; hence, the number of scans should be increased sufficiently.
Previous biochemical assays showed the ability of 4-arylazo-1H-pyrazole-3,5-diamines 1 to inhibit the

HETEROCYCLES, Vol. 83, No. 2, 2011
375
enzymatic activity of cyclin-dependent kinases (CDKs), which are critical regulators of the cell cycle and
some other cellular processes.6 Since the prepared pyrazoles 2a-l contain structural moieties similar to
derivatives 1 we decided to test them for CDK inhibition and antiproliferative activity. However, none of
the prepared compounds inhibited the kinase CDK2/cyclin E, probably due to differences in conformation
between 1 and 2. Arylazo derivatives 1 are able to set almost planar conformation which was proven by
co-crystallization of CAN508 with CDK2 or with CDK9.6,33 In contrast, our benzyl analogues probably
adopt a less planar conformation due to the sp3 configuration of the carbon in the methylene group. Such
molecules cannot enter the active site of CDKs and thus will not inhibit their catalytic activity.
Despite this result that 4-benzyl-1H-pyrazole-3,5-diamines 2a-l are not CDK inhibitors, we tested their
anticancer cytotoxicity under in vitro conditions in two cancer cell lines, K-562 (myeloid leukemia) and
MCF-7 (breast adenocarcinoma). The rationale for performing the cytotoxicity assay was based on a
hypothesis that the cytotoxicity of 4-arylazo-1H-pyrazole-3,5-diamines 1 found in our previous work can
be mediated by interaction(s) with other cellular targets besides CDKs.6 However, the assays showed that
all prepared compounds were not cytotoxic against the two cell lines. These results confirm that
cytotoxicity of 4-arylazo-1H-pyrazole-3,5-diamines 1 is at least partially a consequence of CDK
inhibition in cells.
A novel alternative one-pot procedure to afford benzylmalononitriles 5 from commercially available
benzaldehydes 3 was developed. Sodium cyanoborohydride turned out to be an efficient reagent to
reduce the electron deficient C=C bond in the benzylidenemalononitriles 4. The choice of solvent is
critical for the final step. The cycloaddition of hydrazine with the benzylmalononitriles 5 to give the
desired benzylpyrazoles 2 works best in MeOH. All three steps were evaluated for various derivatives.
None of the prepared pyrazoles 2a-l showed antiproliferative activity against the cell lines K562 or
MCF7.
EXPERIMENTAL
All starting materials used are commercially available. Melting points were determined on a Boetius stage.
The LC/MS analyses were carried out on an UHPLC-MS system consisting of an Accela UHPLC
chromatograph with a photodiode array detector and a TSQ Quantum Access triple quadrupole mass
spectrometer (both Thermo Scientific, CA, USA), using a Nucleodur Gravity C18 column
(Macherey-Nagel, 1.8 µm, 2.1 x 50 mm, Germany) at 30 °C and a flow rate of 800 µL/min. The APCI
source operated at a discharge current of 5 µA, vaporizer temperature of 400 °C and capillary temperature
of 200 °C. The 1H and 13C NMR spectra were measured in DMSO-d6 at 20 °C on a Bruker Avance 300 FT
NMR spectrometer. Elemental analyses were performed using an EA 1108 Elemental Analyzer (Fison
Instruments).

376
HETEROCYCLES, Vol. 83, No. 2, 2011
Typical procedure for the synthesis of 2-benzylidenemalononitriles (4)
The corresponding aldehyde 3 (5 mmol) and piperidine (0.05 mmol) were added to a solution of
malononitrile (5 mmol) in THF (5 mL). The reaction mixture was stirred for 24 h at room temperature
and then was diluted with water (25 mL). The precipitate was collected by filtration, washed with water
and recrystallized from EtOH or a mixture of EtOH and water.
2-(4-Hydroxybenzylidene)malononitrile (4a)
Prepared from 4-hydroxybenzaldehyde. 0.80 g (94%), mp 188–189 °C (EtOH/H2O). MS (-APCI, m/z):
169.0. 1H NMR (300 MHz, DMSO-d6) δ ppm 6.96 (d, J = 8.6 Hz, 2 H), 7.88 (d, J = 8.6 Hz, 2 H), 8.27 (s,
13
1 H), 11.05 (bs, 1 H). C NMR (75 MHz, DMSO-d6) δ ppm 75.1, 114.2, 115.1, 116.6, 122.8, 133.9,
160.5, 163.9. Anal. Calcd for C10H6N2O (170.17): C, 70.58; H, 3.55; N, 16.46. Found: C, 70.42; H, 3.61;
N, 16.26.
2-(4-Nitrobenzylidene)malononitrile (4b)
Prepared from 4-nitrobenzaldehyde. 0.96 g (96%), mp 159-160 °C (EtOH). MS (+APCI, m/z): 198.9. 1H
NMR (300 MHz, DMSO-d6) δ ppm 8.13 (dd, J = 8.8, 1.8 Hz, 2 H), 8.42 (dd, J = 8.8, 1.8 Hz, 2 H), 8.72 (s,
1 H). 13C NMR (75 MHz, DMSO-d6) δ ppm 85.9, 112.5, 113.6, 124.4, 131.5, 136.7, 149.7, 159.3. Anal.
Calcd for C10H5N3O2 (199.17); C, 60.31; H, 2.53; N, 21.10. Found: C, 60.45; H, 2.60; N, 21.18.
2-(2,6-Dimethylbenzylidene)malononitrile (4c)
Prepared from 2,6-dimethylbenzaldehyde. 0.89 g (98%), mp 78-80 °C (EtOH). MS (-APCI, m/z): 181.9.
1H NMR (300 MHz, DMSO-d6) δ ppm 2.27 (s, 6 H), 7.18 (d, J = 7.5 Hz, 2 H), 7.31 (t, J = 7.5 Hz, 1 H),
8.85 (s, 1 H). 13C NMR (75 MHz, DMSO-d6) δ ppm 19.6, 90.4, 112.1, 112.9, 128.0, 130.4, 131.1, 135.8,
165.7. Anal. Calcd for C12H10N2 (182.22); C, 79.10; H, 5.53, N, 15.37. Found: C, 79.22; H, 5.39; N,
15.56.
2-(2,6-Dichlorbenzylidene)malononitrile (4d)
Prepared from 2,6-dichlorbenzaldehyde. 0.89 g (80%), mp 73-74 °C (EtOH). MS (-APCI, m/z): 221.9,
1
13
223.9. H NMR (300 MHz, DMSO-d6) δ ppm 7.57-7.73 (m, 3H), 8.85 (s, 1H). C NMR (75 MHz,
DMSO-d6) δ ppm 93.1, 111.1, 112.1, 129.0, 129.2, 132.7, 133.5, 159.6. Anal. Calcd for C10H4Cl2N2
(223.06); C, 53.85; H, 1.81; N, 12.56. Found: C, 53.96; H, 1.99; N, 12.32.
Typical procedure for the synthesis of benzylmalononitriles (5)
The corresponding aldehyde 3 (5 mmol) and piperidine (0.05 mmol) were added to a solution of
malononitrile (5 mmol) in THF (5 mL). The reaction mixture was stirred for 24 hours at room
temperature, then a solution of acetic acid (0.6 mL) and sodium cyanoborohydride (5 mmol) in THF (15
mL) was added. After three hours of stirring at ambient temperature, THF was evaporated under reduced
pressure and water (30 mL) was added to the residue. The precipitated solid was collected by filtration

HETEROCYCLES, Vol. 83, No. 2, 2011
377
and recrystallized from MeOH or a mixture of MeOH and water (method A). If a precipitate was not
formed, the crude product was extracted with DCM (20 mL) and purified by the column chromatography
(method B).
2-(4-Hydroxybenzyl)malononitrile (5a)
Prepared from 4-hydroxybenzaldehyde (method A). 0.54 g (63%), mp 173-176 °C (MeOH/H2O). MS
(-APCI, m/z): 171.0. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.19 (d, J = 6.7 Hz, 2 H), 4.99 (t, J = 6.8 Hz,
1 H), 6.75 (d, J = 8.4 Hz, 2 H), 7.16 (d, J = 8.6 Hz, 2 H), 9.49 (s, 1 H). 13C NMR (75 MHz, DMSO-d6) δ
ppm 24.6, 34.1, 114.2, 115.4, 124.8, 130.5, 157.1. Anal. Calcd for C10H8N2O (172.18); C, 69.76; H, 4.68;
N, 16.27. Found: C, 69.45; H, 4.47; N, 16.01.
2-(4-Nitrobenzyl)malononitrile (5b)
Prepared from 4-nitrobenzaldehyde (method A). 0.51 g (51%), mp 153-154 °C (MeOH). MS (-APCI,
1
m/z): 199.9. H NMR (300 MHz, DMSO-d6) δ ppm 3.54 (d, J = 7.1 Hz, 2 H), 5.22 (t, J = 7.0 Hz, 1 H),
13
7.67 (d, J = 8.6 Hz, 2 H), 8.27 (d, J = 8.7 Hz, 2 H). C NMR (75 MHz, DMSO-d6) δ ppm 23.8, 33.9,
113.8, 123.8, 130.9, 142.5, 147.3. Anal. Calcd for C10H7N3O2 (201.18); C, 59.70; H, 3.51; N, 20.89.
Found: C, 59.96; H, 3.23; N, 20.57.
2-(2,6-Dimethylbenzyl)malononitrile (5c)
Prepared from 2,6-dimethylbenzaldehyde (method B). 0.45 g (49%), mp 71-73 °C. MS (-APCI, m/z):
183.0. 1H NMR (300 MHz, DMSO-d6) δ ppm 2.37 (s, 6 H), 3.44 (d, J = 8.2 Hz, 2 H), 4.99 (t, J = 8.2 Hz,
13
1 H), 7.04-7.15 (m, 3 H). C NMR (75 MHz, DMSO-d6) δ ppm 19.6, 21.8, 28.9, 114.2, 127.8, 128.5,
131.3, 137.4. Anal. Calcd for C12H12N2 (184.24); C, 78.23; H, 6.57; N, 15.21. Found: C, 78.27; H, 6.61;
N, 15.43.
2-(2,6-Dichlorobenzyl)malononitrile (5d)
Prepared from 2,6-dichlorobenzaldehyde (method A). 0.79 g (70%), mp 84-86 °C (MeOH/H2O). MS
(-APCI, m/z): 222.8. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.68 (d, J = 7.9 Hz, 2 H), 5.17 (t, J = 8.0 Hz,
1 H), 7.43 (t, J = 7.7 Hz, 1 H), 7.57 (d, J = 7.7 Hz, 2 H). 13C NMR (75 MHz, DMSO-d6) δ ppm 21.2, 30.6,
113.4, 129.0, 130.1, 131.1, 135.4. Anal. Calcd for C10H6Cl2N2 (225.07); C, 53.36; H, 2.69; N, 12.45.
Found: C, 53.42; H, 2.78; N, 12.14.
2-(3-Nitrobenzyl)malononitrile (5e)
Prepared from 3-nitrobenzaldehyde (method A). 0.54 g (54%), mp 126-128 °C (MeOH). MS (-APCI,
1
m/z): 199.9. H NMR (300 MHz, DMSO-d6) δ ppm 3.56 (d, J = 7.3 Hz, 2 H), 5.22 (t, J = 7.2 Hz, 1 H),
7.72 (t, J = 8.1 Hz, 1 H), 7.86 (d, J = 7.7 Hz, 1 H), 8.22 (dd, J = 8.2, 1.3 Hz, 1 H), 8.34 (s, 1 H). 13C NMR
(75 MHz, DMSO-d6) δ ppm 24.0, 33.7, 113.8, 122.9, 124.2, 130.2, 136.3, 136.9, 147.8. Anal. Calcd for
C10H7N3O2 (201.18); C, 59.70; H, 3.51; N, 20.89. Found: C, 59.76; H, 3.38; N, 20.65.
2-(4-Methoxybenzyl)malononitrile (5f)

378
HETEROCYCLES, Vol. 83, No. 2, 2011
Prepared from 4-methoxybenzaldehyde (method B). 0.34g (40%), mp 80-81 °C. MS (-APCI, m/z): 185.0.
1H NMR (300 MHz, DMSO-d6) δ ppm 3.26 (d, J = 6.7 Hz, 2 H), 3.75 (s, 3 H), 5.03 (t, J = 6.8 Hz, 1 H),
6.95 (d, J = 8.6 Hz, 2 H), 7.29 (d, J = 8.6 Hz, 2 H). 13C NMR (75 MHz, DMSO-d6) δ ppm 24.5, 33.9, 55.0,
114.0, 114.1, 126.5, 130.5, 158.9. Anal. Calcd for C11H10N2O (186.21); C, 70.95; H, 5.41; N, 15.04.
Found: C, 70.88; H, 5.63; N, 14.99.
2-(3-Hydroxybenzyl)malononitrile (5g)
Prepared from 3-hydroxybenzaldehyde (method B). 0.52 g (60%), mp 77-78 °C. MS (-APCI, m/z): 170.9.
1H NMR (300 MHz, DMSO-d6) δ ppm 3.23 (d, J = 6.7 Hz, 2 H), 5.05 (t, J = 6.8 Hz, 1 H), 6.63 - 6.86 (m,
13
3 H), 7.05-7.26 (m, 1 H), 9.54 (s, 1 H). C NMR (75 MHz, DMSO-d6) δ ppm 24.3, 34.7, 114.2, 115.0,
116.2, 119.9, 129.7, 136.0, 157.5. Anal. Calcd for C10H8N2O (172.18); C, 69.76; H, 4.68; N, 16.27.
Found: C, 69.89; H, 4.47; N, 16.11.
2-(3-Fluorobenzyl)malononitrile (5h)
Prepared from 3-fluorobenzaldehyde (method B). 0.42 g (48%), mp < 65 °C. MS (-APCI, m/z): 172.9. 1H
NMR (300 MHz, DMSO-d6) δ ppm 3.38 (d, J = 6.9 Hz, 2 H), 5.14 (t, J = 7.1 Hz, 1 H), 7.09 - 7.31 (m, 3
13
H), 7.39-7.50 (m, 1 H). C NMR (75 MHz, DMSO-d6) δ ppm 24.0, 34.0, 113.9, 114.6, 114.9, 116.0,
116.3, 125.50, 125.53, 130.6, 130.7, 137.4, 137.5, 160.4, 163.6. Anal. Calcd for C10H7FN2 (174.17); C,
68.96; H, 4.05; N, 16.08. Found: C, 68.81; H, 4.22; N, 16.35.
2-(4-Fluorobenzyl)malononitrile (5i)
Prepared from 4-fluorobenzaldehyde (method A). 0.55 g (64%), mp 107-110 °C (MeOH/H2O). MS
(-APCI, m/z): 172.9. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.34 (d, J = 6.8 Hz, 2H), 5.08 (t, J = 6.9 Hz,
13
1 H), 7.17–7.28 (m, 2 H), 7.37–7.48 (m, 2 H). C NMR (75 MHz, DMSO-d6) δ ppm 24.4, 33.7, 114.0,
115.3, 115.6, 130.91, 130.93, 131.4, 131.5, 160.2, 163.5. Anal. Calcd for C10H7FN2 (174.17); C, 68.96; H,
4.05; N, 16.08. Found: 68.72; H, 4.17; N, 15.84.
2-(2,3,4,5,6-Pentafluorobenzyl)malononitrile (5j)
Prepared from 2,3,4,5,6-pentafluorobenzaldehyde (method A). 0.73 g (60%), mp 95-98 °C (MeOH/H2O).
MS (-APCI, m/z): 244.8. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.58 (d, J = 6.2 Hz, 2 H), 5.19 (t, J = 6.5
Hz, 1 H). 13C NMR (75 MHz, DMSO-d6) δ ppm 22.5, 22.7, 108.4 (t), 113.3, 135.8 (m), 138.3 (m), 139.3
(m), 141.8 (m), 143.9 (m), 146.3 (m). Anal. Calcd for C10H3F5N2 (246.14); C, 48.80; H, 1.23; N, 11.38.
Found: C, 48.95; H, 1.36; N, 11.13.
2-(2-Chloro-6-fluorobenzyl)malononitrile (5k)
Prepared from 2-chloro-6-fluorobenzaldehyde (method A). 0.75 g (72%), mp 119-120 °C (MeOH). MS
(-APCI, m/z): 206.9, 208.9. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.55 (dd, J = 7.3, 1.4 Hz, 2 H), 5.15 (t,
13
J = 7.4 Hz, 1 H), 7.24-7.38 (m, 1 H), 7.39 - 7.53 (m, 2 H). C NMR (75 MHz, DMSO-d6) δ ppm 21.9,
26.37, 26.4, 113.5, 114.7, 115.0, 120.1, 120.4, 125.8, 125.9, 131.2, 131.3, 134.8, 134.9, 159.5, 162.8.

HETEROCYCLES, Vol. 83, No. 2, 2011
379
Anal. Calcd for C10H6ClFN2 (208.62); C, 57.57; H, 2.90; N, 13.43. Found: C, 57.45; H, 3.01; N, 13.22.
2-(2-Fluorobenzyl)malononitrile (5l)
Prepared from 2-fluorobenzaldehyde (method B). 0.60 g (70%), mp 68-70 °C. MS (-APCI, m/z): 173.0.
1H NMR (300 MHz, DMSO-d6) δ ppm 3.41 (d, J = 6.7 Hz, 2 H), 5.14 (t, J = 6.9 Hz, 1 H), 7.16 - 7.34 (m,
2 H), 7.36-7.55 (m, 2 H). 13C NMR (75 MHz, DMSO-d6) δ ppm 23.4, 28.02, 28.05, 113.8, 115.5, 115.7,
121.4, 121.6, 124.7, 124.8, 130.4, 130.5, 131.80, 131.84, 159.0, 162.2. Anal. Calcd for C10H7FN2
(174.17); C, 68.96; H, 4.05; N, 16.08. Found: C, 68.84; H, 4.23; N, 16.20.
2-(2-Nitrobenzyl)malononitrile (5m)
Prepared from 2-nitrobenzaldehyde (method B). 0.97 g (97%), mp 85-86 °C. MS (-APCI, m/z): 200.0. 1H
NMR (300 MHz, DMSO-d6) δ ppm 3.73 (d, J = 7.5 Hz, 2 H), 5.23 (t, J = 7.4 Hz, 1 H), 7.57 - 7.74 (m, 2
H), 7.77-7.91 (m, 1 H), 8.16 (d, J = 8.2 Hz, 1 H). 13C NMR (75 MHz, DMSO-d6) δ ppm 23.3, 32.1, 113.8,
125.5, 129.5, 129.9, 133.2, 134.3, 148.5. Anal. Calcd for C10H7N3O2 (201.18); C, 59.70; H, 3.51; N,
20.89. Found: C, 59.57; H, 3.34; N, 20.61.
2-(3-Methoxybenzyl)malononitrile (5n)
Prepared from 3-methoxybenzaldehyde (method B). 0.35 g (37%), mp < 65 °C. MS (-APCI, m/z): 185.0.
1H NMR (300 MHz, DMSO-d6) δ ppm 3.31 (d, J = 6.9 Hz, 2 H), 3.76 (s, 3 H), 5.11 (t, J = 7.2 Hz, 1 H),
13
6.85-7.01 (m, 3 H), 7.30 (t, J = 7.9 Hz, 1 H). C NMR (75 MHz, DMSO-d6) δ ppm 24.1, 34.5, 55.0,
113.2, 114.0, 115.0, 121.4, 129.7, 136.1, 159.3. Anal. Calcd for C11H10N2O (186.21); C, 70.95; H, 5.41;
N, 15.04. Found: C, 70.69; H, 5.28; N, 14.86.
2-(2-Methoxybenzyl)malononitrile (5o)
Prepared from 2-methoxybenzaldehyde (method B). 0.53 g (57%), mp < 65 °C. MS (-APCI, m/z): 185.0.
1H NMR (300 MHz, DMSO-d6) δ ppm 3.30 (d, J = 6.9 Hz, 2 H), 3.81 (s, 3 H), 5.02 (t, J = 7.2 Hz, 1 H),
13
6.96 (td, J = 7.4, 0.9 Hz, 1 H), 7.05 (d, J = 8.0 Hz, 1 H), 7.24-7.41 (m, 2 H). C NMR (75 MHz,
DMSO-d6) δ ppm 22.7, 29.9, 55.4, 111.0, 114.1, 120.4, 122.2, 129.6, 130.8, 157.3. Anal. Calcd for
C11H10N2O (186.21); C, 70.95; H, 5.41; N, 15.04. Found: C, 70.76; H, 5.21; N, 15.28.
Typical procedure for the synthesis of 4-aryl(methyl)-1H-pyrazole-3,5-diamines (2)
Hydrazine monohydrate (2.75 mmol) was added to a solution of the benzylmalononitrile 5 (2.5 mmol) in
MeOH (17 mL). The reaction mixture was heated at 65°C for 8 hours. After the reaction was complete
(TLC), the solvent was removed under reduced pressure, and the residue was suspended in DCM (20 mL).
The precipitate was collected by filtration and recrystallized from a mixture of MeOH and ethyl acetate.
4-[(3,5-Diamino-1H-pyrazol-4-yl)methyl]phenol (2a)
Prepared from 2-(4-hydroxybenzyl)malononitrile 5a. 0.31 g (60%), mp 203-205 °C. MS (+APCI, m/z):
205.8. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.37 (s, 2 H), 4.21 (NH), 6.61 (d, J = 8.2 Hz, 2 H), 7.00 (d,

380
HETEROCYCLES, Vol. 83, No. 2, 2011
J = 8.2 Hz, 2 H), 9.51 (OH). 13C NMR (75 MHz, DMSO-d6) δ ppm 26.1, 87.4, 114.7, 129.0, 132.4, 149.2,
155.0. Anal. Calcd for C10H12N4O (204.23); C, 58.81; H, 5.92; N, 27.43. Found: C, 58.56; H, 5.77; N,
27.09.
4-(4-Nitrobenzyl)-1H-pyrazole-3,5-diamine (2b)
Prepared from 2-(4-nitrobenzyl)malononitrilu 5b. 0.28 g (47%), mp 155-156 °C. MS (+APCI, m/z): 234.1.
1H NMR (300 MHz, DMSO-d6) δ ppm 3.65 (s, 2 H), 4.43 (bs, NH), 7.48 (d, J = 8.7 Hz, 2 H), 8.11 (d, J =
13
8.7 Hz, 2 H), 10.05 (bs, NH). C NMR (75 MHz, DMSO-d6) δ ppm 26.9, 85.4, 123.2, 129.3, 145.5,
149.5, 151.3. Anal. Calcd for C10H11N5O (233.23); C, 51.50; H, 4.75; N, 30.03. Found: C, 51.64; H, 4.33;
N, 29.89.
4-(2,6-Dimethylbenzyl)-1H-pyrazole-3,5-diamine (2c)
Prepared from 2-(2,6-dimethylbenzyl)malononitrile 5c. 0.15 g (29%), mp 170-173 °C. MS (+APCI, m/z):
217.1. 1H NMR (300 MHz, DMSO-d6) δ ppm 2.25 (s, 6 H), 3.48 (s, 2 H), 3.82 (bs, NH), 6.98–7.03 (m, 3
13
H). C NMR (75 MHz, DMSO-d6) δ ppm 19.8, 22.7, 83.5, 125.8, 128.0, 136.47, 136.52, 148.8. Anal.
Calcd for C12H16N4 (216.28); C, 66.64; H, 7.46; N, 25.90. Found: C, 66.47; H, 7.35; N, 26.12.
4-(2,6-Dichlorobenzyl)-1H-pyrazole-3,5-diamine (2d)
Prepared from 2-(2,6-dichlorobenzyl)malononitrile 5d. 0.38 g (59%), mp 182-190 °C. MS (+APCI, m/z):
257.1; 259.0. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.74 (s, 2 H), 4.26 (bs, NH), 7.25 (t, J = 8.4 Hz, 1 H),
13
7.44 (d, J = 8.1 Hz, 2 H). C NMR (75 MHz, DMSO-d6) δ ppm 24.2, 83.4, 128.6, 134.9, 135.8, 149.0.
Anal. Calcd for C10H10Cl2N4 (257.12); C, 46.71; H, 3.92; N, 21.79. Found: C, 46.56; H, 3.73.; N, 22.04.
4-(3-Nitrobenzyl)-1H-pyrazole-3,5-diamine (2e)
Prepared from 2-(3-nitrobenzyl)malononitrile 5e. 0.42 g (72%), mp 147-149 °C. MS (+APCI, m/z): 234.1.
1H NMR (300 MHz, DMSO-d6) δ ppm 3.67 (s, 2 H), 4.71 (bs, NH), 7.52 (t, J = 7.7 Hz, 1 H), 7.71 (d, J =
13
7.7 Hz, 1 H), 8.00 (d, J = 7.7 Hz, 1 H), 8.09 (s, 1 H). C NMR (75 MHz, DMSO-d6) δ ppm 26.5, 85.8,
120.5, 122.7, 129.4, 135.3, 145.3, 147.7, 149.7. Anal. Calcd for C10H11N5O (233.23); C, 51.50; H, 4.75;
N, 30.03. Found: C, 51.73; H, 4.86; N, 29.85.
4-(4-Methoxybenzyl)-1H-pyrazole-3,5-diamine (2f)
Prepared from 2-(4-methoxybenzyl)malononitrile 5f. 0.48 g (88%), mp 143-145 °C. MS (+APCI, m/z):
219.1. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.43 (s, 2 H); 3.69 (s, 3 H); 4.22 (bs, NH); 6.79 (d, J = 8.6
Hz, 2 H); 7.13 (d, J = 8.6 Hz, 2 H), 9.98 (bs, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 26.1, 54.9, 87.2,
113.3, 129.0, 134.3, 149.1, 157.1. Anal. Calcd for C11H14N4O (218.26); C, 60.53; H, 6.47; N, 25.67.
Found: C, 60.61; H, 6.58; N, 25.34.
3-[(3,5-Diamino-1H-pyrazol-4-yl)methyl]phenol (2g)
Prepared from 2-(3-hydroxybenzyl)malononitrile 5g. 0.34 g (68%), mp 217-219 °C. MS (+APCI, m/z):
205.2. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.44 (s, 2 H), 4.33 (bs, NH), 6.52 (dd, J = 7.8, 1.7 Hz, 1 H),

HETEROCYCLES, Vol. 83, No. 2, 2011
381
6.59 - 6.70 (m, 2 H), 7.01 (t, J = 7.8 Hz, 1 H), 9.56 (bs, OH). 13C NMR (75 MHz, DMSO-d6) δ ppm 27.0,
86.7, 112.4, 115.2, 119.0, 128.8, 143.8, 149.5, 157.3. Anal. Calcd for C10H12N4O (204.23); C, 58.81; H,
5.92; N, 27.43. Found: C, 58.87; H, 5.84; N, 27.36.
4-(3-Fluorobenzyl)-1H-pyrazole-3,5-diamine (2h)
Prepared from 2-(3-fluorobenzyl)malononitrile 5h. 0.23 g (44%), mp 123-124 °C. MS (+APCI, m/z):
207.1. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.52 (s, 2 H), 4.37 (bs, NH), 6.92 (td, J = 8.6, 2.3 Hz, 1 H),
7.01 (d, J = 10.6 Hz, 1 H), 7.08 (d, J = 7.6 Hz, 1 H), 7.19-7.30 (m, 1 H), 10.01 (bs, NH).13C NMR (75
MHz, DMSO-d6) δ ppm 26.6, 86.3, 111.8, 112.1, 114.6, 114.9, 124.28, 124.31, 129.6, 129.7, 145.8, 145.9,
149.5 (bs), 160.6, 163.8. Anal. Calcd for C10H11FN4 (206.22); C, 58.24; H, 5.38; N, 27.17. Found: C,
58.16; H, 5.22; N, 27.36.
4-(4-Fluorobenzyl)-1H-pyrazole-3,5-diamine (2i)
Prepared from 2-(4-fluorobenzyl)malononitrile 5i. 0.26 g (52%), mp 150-152 °C. MS (+APCI, m/z):
1
207.1. H NMR (300 MHz, DMSO-d6) δ ppm 3.49 (s, 2 H), 4.36 (bs, NH), 7.04 (t, J = 8.9 Hz, 2 H),
7.16–7.33 (m, 2 H), 9.96 (bs, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 26.1, 86.8, 114.4, 114.6, 129.8,
129.9, 138.70, 138.73, 149.4, 158.8, 162.0. Anal. Calcd for C10H11FN4 (206.22); C, 58.24; H, 5.38; N,
27.17. Found: C, 58.25; H, 5.57; N, 27.30.
4-(2,3,4,5,6-Pentafluorobenzyl)-1H-pyrazole-3,5-diamine (2j)
Prepared from 2-(2,3,4,5,6-pentafluorobenzyl)malononitrile 5j. 0.23 g (33%), mp 200-202 °C. MS
(+APCI, m/z): 279.1. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.60 (s, 2 H), 4.24 (bs, NH), 10.10 (bs, NH).
13C NMR (75 MHz, DMSO-d6) δ ppm 14.6, 83.7, 115.1, (t), 135.6 (m), 137.4 (m), 138.0 (m), 139.9 (m),
143.3 (m), 145.7 (m), 149.2 (bs). Anal. Calcd for C10H7F5N4 (278.18); C, 43.18; H, 2.54; N, 20.14.
Found: C, 43.25; H, 2.61; N, 20.06.
4-(2-Chloro-6-fluorobenzyl)-1H-pyrazole-3,5-diamine (2k)
Prepared from 2-(2-chloro-6-fluorobenzyl)malononitrile 5k. 0.39 g (66%), mp 161-168 °C. MS (+APCI,
1
m/z): 241.0, 243.0. H NMR (300 MHz, DMSO-d6) δ ppm 3.61 (d, J = 2.0 Hz, 2 H), 4.42 (bs, NH),
7.08-7.23 (m, 1 H), 7.24 - 7.39 (m, 2 H). 13C NMR (75 MHz, DMSO-d6) δ ppm 18.88, 18.92, 84.2, 114.2,
114.5, 125.4, 125.5, 126.4, 126.6, 128.3, 128.4, 133.95, 134.04, 149.0, 159.4, 162.6. Anal. Calcd for
C10H10ClFN4 (240.67); C, 49.91; H, 4.19; N, 23.28. Found: C, 49.85; H, 3.96; N, 23.39.
4-(2-Fluorobenzyl)-1H-pyrazole-3,5-diamine (2l)
Prepared from 2-(2-fluorobenzyl)malononitrile 5l. 0.34 g (67%), mp 150-151 °C. MS (+APCI, m/z):
207.2. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.55 (s, 2 H), 4.33 (bs, NH), 7.00-7.25 (m, 4 H), 9.98 (bs,
13
NH). C NMR (75 MHz, DMSO-d6) δ ppm 19.77, 19.83, 84.2, 114.5, 114.8, 123.98, 124.02, 127.2,
127.3, 128.5, 128.7, 130.2, 130.3, 149.6, 158.9, 162.0. Anal. Calcd for C10H11FN4 (206.22); C, 58.24; H,
5.38; N, 27.17. Found: C, 58.18; H, 5.33; N, 26.90.

382
HETEROCYCLES, Vol. 83, No. 2, 2011
ACKNOWLEDGEMENTS
We are grateful to grants MSM6198959216 from the Ministry of Education, Youth and Sports, and
204/08/0511 from the Czech Science Foundation.
REFERENCES
1. D. Fabbro, S. Ruetz, E. Buchdunger, S.W. Cowan-Jacob, G. Fendrich, J. Liebetanz, J. Mestan, T.
O'Reilly, P. Traxler, B. Chaudhuri, H. Fretz, J. Zimmermann, T. Meyer, G. Caravatti, P. Furet, and P.
W. Manley, Pharmacol. Ther., 2002, 93, 79.
2. L. N. Johnson, Biochem. Soc. Trans., 2009, 37, 627.
3. L. N. Johnson, Q. Rev. Biophys., 2009, 42, 1.
4. P. Cohen, Nat. Rev. Drug Discov., 2002, 1, 309.
5. E. Weisberg, P. W. Manley, S. W. Cowan-Jacob, A. Hochhaus, and J. D. Griffin, Nat. Rev. Cancer,
2007, 7, 345.
6. V. Kryštof, P. Cankař, I. Fryšová, J. Slouka, G. Kontopidis, P. Džubák, M. Hajduch, J. Srovnal, W.
F. de Azevedo, Jr., M. Orság, M. Paprskářová, J. Rolčík, A. Látr, P. M. Fischer, and M. Strnad, J.
Med. Chem., 2006, 49, 6500.
7. J. Peng, Y. Zhu, J. T. Milton, and D. H. Price, Gene. Dev., 1998, 12, 755.
8. M. Sano, M. Abdellatif, H. Oh, M. Xie, L. Bagella, A. Giordano, L. H. Michael, F. J. DeMayo, and
M. D. Schneider, Nat. Med., 2002, 8, 1310.
9. Y. Zhu, T. Pe’ery, J. Peng, Y. Ramanathan, N. F. Marshall, T. K. Marshall, B. A. Amendt, M. B.
Mathews, and D. H. Price, Gene. Dev., 1997, 11, 2622.
10. H. S. Y. Mancebo, G. Lee, J. Flygare, J. Tomassini, P. Luu, Y. Zhu, J. Peng, C. Blau, D. Hazuda, D.
Price, and O. Flores, Gene. Dev., 1997, 11, 2633.
11. D. E. MacCallum, J. Melville, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D. P. Lane,
and S. R. Green, Cancer Res., 2005, 65, 5399.
12. R. Chen, M. J. Keating, V. Gandhi, and W. Plunkett, Blood, 2005, 106, 2513.
13. M. E. M. Noble, J. A. Endicott, and L. N. Johnson, Science, 2004, 303, 1800.
14. T. Tanaka, Food Chem. Toxicol., 2006, 44, 179.
15. E. Engel, H. Ulrich, R. Vasold, B. König, M. Landthaler, R. Süttinger, and W. Bäumler,
Dermatology, 2008, 216, 76.
16. B. Stanovnik and J. Svete, Science of Sythesis, 2002, 12, 15.
17. J. J. Vaquero, L. Fuentes, J. C. Del Castillo, M. I. Perez, J. L. Garcia, and J. L. Soto, Synthesis, 1987,
33.
18. V. J. Ram, M. Nath, B. Saraswat, and G. K. Patnaik, Bioorg. Med. Chem. Lett., 1995, 5, 1537.

HETEROCYCLES, Vol. 83, No. 2, 2011
383
19. F. Diez-Barra, A. de la Hoz, A. Moreno, and P. Sánchez-Verdú, Synthesis, 1989, 391.
20. B. C. Ranu, S. Banerjee, and R. Jana, Tetrahedron, 2007, 63, 776.
21. B. C. Ranu and R. Jana, Eur. J. Org. Chem., 2006, 3767.
22. J. Han, Y. Xu, Y. Su, X. She, and X. Pan, Catal. Commun., 2008, 9, 2077.
23. J. S. Yadav, B. V. S. Reddy, A. K. Basak, B. Visali, A. V. Narsaiah, and K. Nagaiah, Eur. J. Org.
Chem., 2004, 546.
24. M. L. Deb and P. J. Bhuyan, Tetrahedron Lett., 2005, 46, 6453.
25. J. C. Dunham, A. D. Richardson, and R. E. Sammelson, Synthesis, 2006, 680.
26. K. Nanjo, K. Suzuki, and M. Sekiya, Chem. Pharm. Bull., 1977, 25, 2396.
27. X. Zhu, H. Zou, P. Yuan, Y. Liu, L. Cao, and J. Cheng, J. Chem. Soc., Perkin Trans. 2, 2000, 1857.
28. S. J. Garden, C. R. W. Guimaraes, M. B. Correa, C. A. F. Oliveira, A. C. Pinto, and R. B. Alencastro,
J. Org. Chem., 2003, 68, 8815.
29. E. Booker and U. J. Eisner, J. Chem. Soc., Perkin Trans. 1, 1975, 929.
30. R. O. Hutchins and N. R. Natale, Synthesis, 1979, 281.
31. P. Mulder, G. Litwinienko, S. Lin, P. D. MacLean, L. R. C. Barclay, and K. U. Ingold, Chem. Res.
Toxicol., 2006, 19, 79.
32. S. M. Al-Mousawi, M. S. Moustafa, and M. H. Elnagdi, Heterocycles, 2008, 75, 1371.
33. S. Baumli, manuscript in preparation.